South San Francisco, CA, United States of America

Ada Hui

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Genentech, Inc.. Active years: 2016.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ada Hui - Innovator in Anti-PCSK9 Antibodies

Introduction

Ada Hui is a prominent inventor based in South San Francisco, CA. She has made significant contributions to the field of biotechnology, particularly in the development of anti-PCSK9 antibodies. Her work is crucial in advancing treatments for cholesterol management and cardiovascular health.

Latest Patents

Ada Hui holds a patent for "Anti-PCSK9 antibodies, formulations, dosing, and methods of use." This invention provides innovative solutions through the development of anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using these antibodies. Her patent is a testament to her expertise and dedication to improving healthcare.

Career Highlights

Ada Hui is currently employed at Genentech, Inc., a leading biotechnology company known for its focus on innovative medicines. Her role at Genentech allows her to collaborate with other talented professionals in the field, contributing to groundbreaking research and development.

Collaborations

Some of her notable coworkers include Yan Wu and Cecilia Pui Chi Chiu. Together, they work on advancing the understanding and application of anti-PCSK9 antibodies, enhancing the potential for new therapeutic options.

Conclusion

Ada Hui's contributions to the field of biotechnology, particularly through her patent on anti-PCSK9 antibodies, highlight her role as an innovator. Her work at Genentech, along with her collaborations, positions her as a key figure in the ongoing efforts to improve cardiovascular health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…